RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and East
March 15, 2016 7:05 AM EDTSAN DIEGO, March 15, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) will host a conference call this afternoon to discuss the strategic acquisition of all U.S. rights to Contrave® and the Mysimba® commercialization and distribution agreement with Valeant Pharmaceuticals... More
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and Eastern
March 15, 2016 7:00 AM EDTSAN DIEGO, March 15, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. The distribution agreement between Valeant Holdings Ireland and Orexigen's wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., includes 12 countries where Mysimba has been approved for marketing in the European Union (EU): Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia, Lithuania, Estonia, Poland, Latvia, Bulgaria, and Romania. The agreement also extends to several non-EU countries where Valeant will apply for marketing authorization: Serbia,... More
Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine
March 15, 2016 7:00 AM EDTSAN DIEGO, March 15, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the United States rights to Contrave® (naltrexone HCl / bupropion HCl extended release), the market leading branded prescription medicine for the treatment of obesity. The acquisition is subject to the parties' receipt of clearance under the Hart-Scott-Rodino Antitrust Improvement Act ("HSR Act"). Upon completion of the acquisition, including the agreed upon transition period, Orexigen will own all rights to Contrave in nearly all global... More
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United States
March 15, 2016 7:00 AM EDTSAN DIEGO and DEERFIELD, Ill., and OSAKA, Japan, March 15, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502) (collectively "Takeda"), today announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE® (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for chronic weight management. Completion of the transaction is subject to the parties' receipt of clearance under the... More
